Celyad Oncology SA
Celyad Oncology SA (CYAD.BR) Stock Overview
Explore Celyad Oncology SA’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
14.4M
P/E Ratio
-2.63
EPS (TTM)
$-1.36
ROE
0.91%
CYAD.BR Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Celyad Oncology SA (CYAD.BR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 45.47, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.18.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -2.63 and a market capitalization of 14.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Matthew R. Kane
17
Axis Business Park, Mont-Saint-Guibert
2013